Best CT and MRI Contrast Media Calculator
Optimize clinical workflows with our advanced contrast media calculator, designed for precise, patient-specific dosing of CT iodinated contrast and MRI gadolinium-based agents. Streamline your imaging protocols with built-in tools for Lean Body Weight (LBW), BSA, and eGFR safety assessments. Access precise injection profiles, real-time pressure curves, and institutional annual volume projections to reduce contrast waste and ensure accurate CT contrast dose and gadolinium dose calculations every time.
CT Iodinated Contrast Calculator
Complete Patient Dose Analysis
Annual Volume Projection per Scanner
Protocol recommendation will appear here.
CT Contrast Protocol Reference
| Exam Type | Iodine Dose (mg I/kg) | IDR (g I/s) | Typical Volume (mL) | Injection Rate |
|---|---|---|---|---|
| Pulmonary CTA (CTPA) | 300-400 | 1.5-2.0 | 60-80 | 4-5 mL/s |
| Coronary CTA | 300-400 | 1.8-2.2 | 60-90 | 4-6 mL/s |
| Aortic / Peripheral CTA | 350-450 | 1.5-2.0 | 80-120 | 3-5 mL/s |
| Abdominal/Pelvic CT | 400-600 | 1.0-1.5 | 80-120 | 2-4 mL/s |
| Hepatic (late arterial + portal) | 500-600 | 1.2-1.5 | 100-150 | 3-4 mL/s |
| Renal CT | 400-500 | 1.0-1.5 | 80-100 | 2-3 mL/s |
| Low-dose / Follow-up | 200-300 | 0.8-1.2 | 40-60 | 2-3 mL/s |
Renal Safety: For eGFR < 30 mL/min/1.73m2, consider alternative imaging or dialysis planning. For eGFR 30-44, use minimum diagnostic dose and hydrate. Always follow institutional policy and ACR guidelines.
| eGFR Range | CKD Stage | Creatinine Context | CIN Risk Guidance | Recommended Protocol |
|---|---|---|---|---|
| ≥ 60 mL/min/1.73m2 | Normal / G1-G2 | Typically < 1.2 mg/dL (varies by age/muscle mass) | Low CIN risk. Standard hydration and standard contrast dose are acceptable. No special precautions beyond routine protocol. | Standard iodinated contrast protocol. Oral or IV hydration per institutional policy. |
| 45 – 59 mL/min/1.73m2 | G3a (Mild-Moderate) | Elevated but variable; eGFR calculation required | Mild CIN risk. Ensure pre- and post-hydration. Use minimum diagnostic iodine dose. Consider iso-osmolar contrast agents. | Hydrate before and after exam. Use lowest effective iodine dose. Monitor creatinine 48-72h post-scan if high-risk. |
| 30 – 44 mL/min/1.73m2 | G3b (Moderate-Severe) | Usually > 1.5 mg/dL; confirm with CKD-EPI | Moderate CIN risk. Use minimum diagnostic dose with iso-osmolar agent. Aggressive hydration. Obtain informed consent. Consider alternative imaging (MRI, US). | Iso-osmolar contrast preferred. IV hydration (1-1.5 mL/kg/h) before and after. Limit iodine load to < 300 mg I/kg if possible. |
| 15 – 29 mL/min/1.73m2 | G4 (Severe) | Typically > 2.0–3.0 mg/dL | High CIN risk. Strongly consider non-contrast or alternative imaging. If essential, use minimum dose with nephrology consultation. Plan dialysis if applicable. | Nephrology consult required. Use absolute minimum diagnostic dose. IV sodium bicarbonate or N-acetylcysteine per protocol. Dialysis planning if on HD. |
| < 15 mL/min/1.73m2 | G5 (Kidney Failure) | Usually > 4.0 mg/dL or on dialysis | Very high CIN risk. Avoid iodinated contrast unless life-threatening emergency. If on dialysis, contrast can be given with post-procedure dialysis within 24h. | Avoid unless absolutely essential. If on HD, schedule dialysis within 24h post-injection. Use minimum dose. |
| AKI (any eGFR) | Acute Kidney Injury | Rapidly rising creatinine or oliguria | Postpone non-urgent CT. If emergency imaging required, use minimum dose with aggressive hydration. Coordinate with nephrology. | Delay elective studies. Use minimum diagnostic dose. Nephrology consult for all emergency cases. |
Creatinine Note: Serum creatinine alone is not sufficient for CIN risk stratification because it varies with age, sex, muscle mass, and diet. Always calculate eGFR using the CKD-EPI equation (built into this calculator) before making contrast decisions. For example, a creatinine of 1.2 mg/dL may be normal in a young male but represents eGFR < 60 in an elderly female.
Hydration Protocol: Oral hydration (500 mL water before, 500 mL after) is standard for outpatients. IV hydration with normal saline (1 mL/kg/h for 6-12h before and after) is recommended for inpatients with eGFR < 60. Sodium bicarbonate protocols may be used for high-risk patients per institutional guidelines.
MRI Gadolinium Contrast Calculator
Complete Patient Dose Analysis
Annual Volume Projection per Scanner
Protocol recommendation will appear here.
MRI GBCA Protocol Reference
| Agent | Concentration | Standard Dose | MRA Dose | Stability |
|---|---|---|---|---|
| Gadobutrol (Gadovist) | 1.0 M | 0.1 mmol/kg | 0.1-0.2 mmol/kg | Macrocyclic |
| Gadoterate (Dotarem) | 0.5 M | 0.1 mmol/kg | 0.1-0.2 mmol/kg | Macrocyclic |
| Gadobenate (MultiHance) | 0.5 M | 0.1 mmol/kg | 0.1-0.2 mmol/kg | Linear |
| Gadoxetate (Eovist) | 0.25 M | 0.025 mmol/kg | 0.1 mmol/kg | Linear |
| Gadoteridol (ProHance) | 0.5 M | 0.1 mmol/kg | 0.1-0.2 mmol/kg | Macrocyclic |
| Gadopentetate (Magnevist) | 0.5 M | 0.1 mmol/kg | 0.1-0.2 mmol/kg | Linear |
| Gadodiamide (Omniscan) | 0.5 M | 0.1 mmol/kg | 0.1-0.2 mmol/kg | Linear |
| Gadopiclenol (Elucirem) | 0.5 M | 0.05 mmol/kg | 0.1 mmol/kg | Macrocyclic (High Relaxivity) |
| Gadopiclenol (Amblevist) | 0.5 M | 0.05 mmol/kg | 0.1 mmol/kg | Macrocyclic (High Relaxivity) |
NSF Risk: Avoid linear GBCAs (gadodiamide, gadopentetate, gadobenate, gadoxetate) in patients with eGFR < 30 mL/min/1.73m2 or acute kidney injury. Use macrocyclic agents (gadobutrol, gadoterate, gadoteridol, gadopiclenol) instead. For eGFR 30-59, use lowest diagnostic dose.
| eGFR Range | CKD Stage | Creatinine Context | GBCA Safety Guidance | Recommended Agents |
|---|---|---|---|---|
| ≥ 60 mL/min/1.73m2 | Normal / G1-G2 | Typically < 1.2 mg/dL (varies by age/muscle mass) | Safe for all GBCAs. No special precautions beyond standard protocol. Monitor for allergic reactions. | All agents acceptable. Macrocyclic preferred for repeated dosing. |
| 45 – 59 mL/min/1.73m2 | G3a (Mild-Moderate) | Elevated but variable; eGFR calculation required | Caution. Prefer macrocyclic agents. Use lowest diagnostic dose. Ensure hydration before and after exam. | Macrocyclic strongly preferred (gadobutrol, gadoterate, gadoteridol, gadopiclenol). |
| 30 – 44 mL/min/1.73m2 | G3b (Moderate-Severe) | Usually > 1.5 mg/dL; confirm with CKD-EPI | Moderate risk. Avoid linear GBCAs if possible. Use macrocyclic only with minimum dose. Obtain informed consent. Hydrate aggressively. | Macrocyclic only (gadobutrol, gadoterate, gadoteridol, gadopiclenol). Avoid linear agents. |
| 15 – 29 mL/min/1.73m2 | G4 (Severe) | Typically > 2.0–3.0 mg/dL | High risk. Avoid linear GBCAs (NSF risk). Macrocyclic agents only with nephrology consultation. Consider dialysis planning if essential. Postpone non-urgent studies. | Macrocyclic only with minimum dose. Nephrology consult required. |
| < 15 mL/min/1.73m2 | G5 (Kidney Failure) | Usually > 4.0 mg/dL or on dialysis | Contraindicated unless life-threatening. Avoid all GBCAs unless absolutely essential. If unavoidable, use macrocyclic with immediate dialysis coordination. | Macrocyclic only if essential. Dialysis within 2 hours post-injection if performed. |
| AKI (any eGFR) | Acute Kidney Injury | Rapidly rising creatinine or oliguria | Postpone non-urgent MRI. If emergency imaging required, use macrocyclic agent at lowest dose. Coordinate with nephrology. | Macrocyclic only at lowest diagnostic dose. |
Creatinine Note: Serum creatinine alone is not sufficient for risk stratification because it varies with age, sex, muscle mass, and diet. Always calculate eGFR using the CKD-EPI equation (built into this calculator) before making GBCA decisions. For example, a creatinine of 1.2 mg/dL may be normal in a young male but represents eGFR < 60 in an elderly female.
High-Relaxivity Agents: Gadopiclenol (Elucirem, Amblevist) has approximately 2–3× the relaxivity of conventional macrocyclic agents. This allows for a reduced dose (0.05 mmol/kg standard; 0.1 mmol/kg for MRA) while maintaining equivalent or superior enhancement. This is particularly advantageous in patients with renal impairment where minimizing gadolinium exposure is desired.
Explore SATMED Health Solutions
Discover our complete portfolio of medical imaging and patient care products.
References
- ACR Manual on Contrast Media, 2023 Edition. American College of Radiology.
- European Society of Urogenital Radiology (ESUR) Contrast Media Safety Committee Guidelines, 10.0 Edition, 2018.
- Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology. 2010;256(1):32-61.
- McDonald RJ et al. Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging. Radiology. 2015;275(3):772-782.
- Levey AS et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. (CKD-EPI)
- FDA Drug Safety Communication: Gadolinium Retention in the Body. U.S. Food and Drug Administration, 2017/2018.

1 Comment
Comments are closed.